Christopher Cahoon, PharmD elucidates the literature pertaining to injectable cabotegravir and rilpivirine as HIV therapy options.
For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.
You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
